CEO Andrew Dudum told CNBC the company is confident customers will be able to access a consistent supply of the injections
This slows the emptying of the stomach and reduces appetite, which can assist in weight loss with PCOS
This precision-wellness approach recognizes that metabolic benefit, cardiovascular protection, and weight loss occur through multiple pathwaysand your genetics may influence which benefits emerge first or most prominently
The question became whether humans share this vulnerability
Appetite Regulation GLP-1 receptor agonists influence the brains appetite centers, leading to a reduction in hunger and cravings
Sources Eli Lilly and Company: Tirzepatide for the Treatment of Obesity The New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity Diabetes Care: Efficacy and Safety of Tirzepatide for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis American Diabetes Association: Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes Obesity (Silver Spring): Predictors of Weight Loss Response with Once-Weekly Semaglutide Treatment NPR: Report on Compounded Tirzepatide and Legal Issues Important Medical Information and Disclaimers Important Current Status Update : On March 19, 2025, the FDA ended enforcement discretion for compounded tirzepatide